Pharmacogenomics and individualized drug therapy.
By M. Eichelbaum, Magnus Ingelman-Sundberg, William E. Evans. Annual Review of Medicine, 2006
673 citations recorded by the source corpus.
Subfields: Molecular Biology, Pharmacology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/232bd9f51da98966ee7a05a93a1215fe1f29034b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pharmacology
Citations in the corpus
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Theoretically, variations at even a single base (SNPs) or sets of closely-related SNPs (haplotypes) in genes involved in the pharmacokinetic and pharmacodynamic pathways at any stage could affect the overall drug response of an individual [27,28].”
- Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes (2009, neutral): “215 gelman-Sundberg, 2004; Eichelbaum et al., 2006).”
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “In general, it can be estimated that 20–25% of all drug therapies are influenced by such polymorphism to an extent that therapy outcome is affected (Ingelman-Sundberg, 2004) and the CYP play a critical role, as these enzymes are responsible for about 80% of all phase I drug metabolism (Eichelbaum et”
- Cytochrome P450 Enzymes and Drug Metabolism in Humans (2021, background): “CYPs, as the most diverse catalysts known in biochemistry, contribute to interindividual variations in drug responses, resulting from genetic and epigenetic variants, as well as environmental factors, such as gender, age, nutriture, disease states, and pathophysiological factors [13].”
- Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013, neutral): “It is estimated that genetic variation overall accounts only for about 15–30 % of inter-individual differences observed in drug metabolism and response (Eichelbaum et al. 2006).”